Published in Br J Surg on April 01, 2008
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol (2015) 0.97
Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology (2011) 0.97
Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile. Clin Breast Cancer (2012) 0.89
Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors. World J Surg Oncol (2013) 0.79
Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes - what does it all mean? BMC Med (2015) 0.77
Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA (2001) 3.73
Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol (2004) 2.95
Triple-negative breast cancer--current status and future directions. Ann Oncol (2009) 2.78
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56
Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg (2006) 2.54
Presentation, treatment, and outcome of local recurrence afterskin-sparing mastectomy and immediate breast reconstruction. Ann Surg Oncol (1999) 1.92
Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res (2001) 1.76
Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst (2001) 1.68
Radiofrequency ablation of solid tumors. Cancer J (2001) 1.66
Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol (2011) 1.64
Accuracy of amplitude-integrated electroencephalography in the prediction of neurodevelopmental outcome in asphyxiated infants receiving hypothermia treatment. Acta Paediatr (2013) 1.58
Local recurrence and survival among black women with early-stage breast cancer treated with breast-conservation therapy or mastectomy. Ann Surg Oncol (1999) 1.50
Burnout and career satisfaction among surgical oncologists compared with other surgical specialties. Ann Surg Oncol (2010) 1.49
Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin alpha). Reprod Biomed Online (2006) 1.47
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Stereotaxic aspiration biopsy in the evaluation of mammographically detected clustered microcalcification. Cancer (1998) 1.42
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol (2013) 1.41
Molecular Profiling Using Breast Cancer Subtype to Plan for Breast Reconstruction. Plast Reconstr Surg (2017) 1.39
Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol (2006) 1.25
Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg (2001) 1.22
Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann Oncol (2008) 1.21
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer (2005) 1.18
Atomic order and cluster energetics of a 17 wt% Si-based glass versus the liquid phase. J Phys Condens Matter (2013) 1.17
Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist (2001) 1.17
The effect of under-treatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol (2010) 1.15
Feasibility of immediate breast reconstruction for locally advanced breast cancer. Ann Surg Oncol (1999) 1.12
Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2000) 1.09
RMCSANS--modelling the inter-particle term of small angle scattering data via the reverse Monte Carlo method. J Phys Condens Matter (2010) 1.08
Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. J Acquir Immune Defic Syndr (1999) 1.07
Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol (2008) 1.07
Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol (2008) 1.07
Malignant melanoma metastatic to the breast: a report of seven cases diagnosed by fine-needle aspiration cytology. Cancer (1998) 1.06
Predictors and impact of patients lost to follow-up in a long-term randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.06
Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg (2001) 1.06
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer (2012) 1.05
Propionibacterium acnes as the cause of endocarditis in a liver transplant recipient. Clin Infect Dis (2000) 1.05
Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis. Oncogene (1996) 1.05
Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. J Infect Dis (2000) 1.04
Reduction mammoplasty improves breast conservation therapy in patients with macromastia. Am J Surg (2001) 1.01
The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res Treat (2013) 1.01
Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res (2001) 1.00
Mammotome core biopsy for mammary microcalcification: analysis of 160 biopsies from 142 women with surgical and radiologic followup. Cancer (2001) 1.00
Coincident renal cell carcinoma and nonHodgkin's lymphoma: the M. D. Anderson experience and review of the literature. J Urol (1998) 0.98
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol (2007) 0.97
Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol (2001) 0.96
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol (2013) 0.96
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Ann Oncol (2013) 0.96
Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol (2000) 0.95
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol (2007) 0.95
Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle (2005) 0.95
Fine-needle aspiration cytology of Hodgkin disease: a study of 89 cases with emphasis on false-negative cases. Cancer (2001) 0.94
Myoepithelial cells actively proliferate during atrophy of rat parotid gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1996) 0.93
Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg (2000) 0.92
Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat (2004) 0.92
Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J (2001) 0.92
Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer (2013) 0.90
Which threshold for ER positivity? a retrospective study based on 9639 patients. Ann Oncol (2014) 0.90
Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat (2012) 0.90
Plasmacytoma of the breast. A report of two cases diagnosed by aspiration biopsy. Acta Cytol (2000) 0.88
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol (2008) 0.87
Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res (1998) 0.87
Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant (2012) 0.87
Chemotherapy-induced histologic changes in mastectomy specimens and their potential significance. Breast (2001) 0.86
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res (1998) 0.85
Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res (1996) 0.85
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma (1998) 0.85
Concurrent paclitaxel and radiation therapy for breast cancer. Semin Radiat Oncol (1999) 0.85
Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol (2000) 0.84
Prevalence and patterns of use of concomitant medications among participants in three multicenter human immunodeficiency virus type I clinical trials. AIDS Clinical Trials Group (ACTG). J Acquir Immune Defic Syndr (1994) 0.84
Efficacy of cyclosporin in the treatment of atopic dermatitis in dogs--combined results from two veterinary dermatology referral centres. Aust Vet J (2004) 0.84
Adverse prognostic significance of infraclavicular lymph nodes detected by ultrasonography in patients with locally advanced breast cancer. Am J Surg (2001) 0.84
Promises and caveats of in silico biomarker discovery. Br J Cancer (2008) 0.83
Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. Cancer (2000) 0.82
Educational review: role of the surgeon in hereditary breast cancer. Ann Surg Oncol (2001) 0.81
Invasive carcinoma in clinically suspicious breast masses diagnosed as adenocarcinoma by fine-needle aspiration. Cancer (2000) 0.81
Lac repressor inducible gene expression in human breast cancer cells in vitro and in a xenograft tumor. Biotechniques (1997) 0.81
Changes in nurse cell nuclei during synchronous infection with Trichinella spiralis. J Parasitol (1991) 0.81
The incidence of positive margins with breast conserving therapy following mammotome biopsy for microcalcification. J Surg Oncol (2000) 0.81
Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum Gene Ther (1996) 0.81
Use of E-cadherin and CD44 aids in the differentiation between reactive mesothelial cells and carcinoma cells in pelvic washings. Cancer (2000) 0.81
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer (2008) 0.81
Transfected neu oncogene induces human prostate cancer metastasis. Prostate (1996) 0.80
Anaphylaxis during breast cancer lymphatic mapping. Surgery (2001) 0.80
Characterization of foam cells in nipple aspirate fluid. Diagn Cytopathol (2002) 0.80
Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer (1999) 0.80
Utility of breast sentinel lymph node biopsy using day-before-surgery injection of high-dose 99mTc-labeled sulfur colloid. Ann Surg Oncol (2001) 0.80
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol (2012) 0.79
Nanometer range correlations between molecular orientations in liquids of molecules with perfect tetrahedral shape: CCl(4), SiCl(4), GeCl(4), and SnCl(4). J Chem Phys (2009) 0.79
Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res (2000) 0.79